NovoCure Limited

94.22-0.8700-0.91%Vol 740.17K1Y Perf 37.18%
Feb 3rd, 2023 16:00 DELAYED
BID92.00 ASK97.55
Open93.62 Previous Close95.09
Pre-Market- After-Market94.10
 - -  -0.12 -0.13%
Target Price
107.43 
Analyst Rating
Hold 2.75
Potential %
14.02 
Finscreener Ranking
     40.80
Insiders Trans % 3/6/12 mo.
-100/-100/-89 
Value Ranking
     39.72
Insiders Value % 3/6/12 mo.
-100/-100/-89 
Growth Ranking
★★     45.24
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-89 
Income Ranking
 —    -
Price Range Ratio 52W %
59.44 
Earnings Rating
Strong Buy
Market Cap9.89B 
Earnings Date
23rd Feb 2023
Alpha0.03 Standard Deviation0.18
Beta0.95 

Today's Price Range

92.2095.13

52W Range

56.39120.03

5 Year PE Ratio Range

-762.901.23K

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.65%
1 Month
33.59%
3 Months
33.51%
6 Months
25.83%
1 Year
37.18%
3 Years
9.48%
5 Years
342.35%
10 Years
-

TickerPriceChg.Chg.%
NVCR94.22-0.8700-0.91
AAPL154.503.68002.44
GOOG105.22-3.5800-3.29
MSFT258.35-6.2550-2.36
XOM111.920.77000.69
WFC47.580.35000.74
JNJ164.61-0.9300-0.56
FB196.640.99000.51
GE81.96-1.9800-2.36
JPM141.092.15001.55
 
ProfitabilityValueIndustryS&P 500US Markets
78.70
-13.70
-11.70
-12.80
-13.49
RevenueValueIndustryS&P 500US Markets
409.41M
3.90
23.21
35.63
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.30-0.2516.67
Q02 2022-0.14-0.23-64.29
Q01 2022-0.17-0.0476.47
Q04 2021-0.10-0.25-150.00
Q03 2021-0.06-0.13-116.67
Q02 20210.02-0.14-800.00
Q01 20210.01-0.04-500.00
Q04 20200.130.04-69.23
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.313.13Positive
12/2022 FY-0.845.62Positive
3/2023 QR-0.2820.00Positive
12/2023 FY-1.091.80Positive
Next Report Date23rd Feb 2023
Estimated EPS Next Report-0.32
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume740.17K
Shares Outstanding104.95K
Shares Float78.86M
Trades Count13.47K
Dollar Volume69.40M
Avg. Volume1.16M
Avg. Weekly Volume865.01K
Avg. Monthly Volume1.69M
Avg. Quarterly Volume931.44K

NovoCure Limited (NASDAQ: NVCR) stock closed at 94.22 per share at the end of the most recent trading day (a -0.91% change compared to the prior day closing price) with a volume of 740.17K shares and market capitalization of 9.89B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1023 people. NovoCure Limited CEO is Asaf Danziger.

The one-year performance of NovoCure Limited stock is 37.18%, while year-to-date (YTD) performance is 28.45%. NVCR stock has a five-year performance of 342.35%. Its 52-week range is between 56.39 and 120.03, which gives NVCR stock a 52-week price range ratio of 59.44%

NovoCure Limited currently has a PE ratio of -141.60, a price-to-book (PB) ratio of 25.69, a price-to-sale (PS) ratio of 23.39, a price to cashflow ratio of 232.80, a PEG ratio of 2.32, a ROA of -7.69%, a ROC of -8.12% and a ROE of -20.54%. The company’s profit margin is -13.49%, its EBITDA margin is -11.70%, and its revenue ttm is $409.41 Million , which makes it $3.90 revenue per share.

Of the last four earnings reports from NovoCure Limited, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. NovoCure Limited’s next earnings report date is 23rd Feb 2023.

The consensus rating of Wall Street analysts for NovoCure Limited is Hold (2.75), with a target price of $107.43, which is +14.02% compared to the current price. The earnings rating for NovoCure Limited stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

NovoCure Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

NovoCure Limited has a Buy technical analysis rating based on Technical Indicators (ADX : 19.16, ATR14 : 5.36, CCI20 : 23.39, Chaikin Money Flow : -0.09, MACD : 2.70, Money Flow Index : 46.78, ROC : 1.50, RSI : 57.75, STOCH (14,3) : 84.56, STOCH RSI : 0.76, UO : 58.87, Williams %R : -15.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of NovoCure Limited in the last 12-months were: Asaf Danziger (Sold 0 shares of value $-1 627 125 ), Asaf Danziger (Sold 212 500 shares of value $23 106 230 ), Ashley Cordova (Sold 0 shares of value $0 ), Ashley Cordova (Sold 3 349 shares of value $247 898 ), Ely Benaim (Sold 12 914 shares of value $901 551 ), Frank Leonard (Sold 0 shares of value $-468 670 ), Frank Leonard (Sold 138 762 shares of value $12 188 798 ), Jeryl L. Hilleman (Sold 407 shares of value $28 331 ), Pritesh Shah (Sold 13 974 shares of value $1 007 237 ), Todd Christopher Longsworth (Sold 5 406 shares of value $384 378 ), Uri Weinberg (Sold 0 shares of value $-91 540 ), Uri Weinberg (Sold 8 143 shares of value $945 756 ), Wilhelmus C. M. Groenhuysen (Sold 7 089 shares of value $506 095 ), William F. Doyle (Sold 3 222 shares of value $225 493 ), William Patrick Burke (Sold 3 122 shares of value $227 084 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (37.50 %)
4 (50.00 %)
3 (37.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (37.50 %)
2 (25.00 %)
3 (37.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (25.00 %)
2 (25.00 %)
2 (25.00 %)
Summary RatingHold
2.75
Moderate Buy
2.50
Hold
2.75

NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

CEO: Asaf Danziger

Telephone: +44 1534756700

Address: Grenville Street, Saint Helier JE2 4UF, , JE

Number of employees: 1 023

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

52%48%

Bearish Bullish

56%44%

TipRanks News for NVCR

Thu, 12 Jan 2023 11:15 GMT NovoCure (NVCR) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 06 Jan 2023 12:11 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), NovoCure (NVCR) and eFFECTOR Therapeutics (EFTR)

- TipRanks. All rights reserved.

Fri, 29 Jul 2022 12:24 GMT NovoCure (NVCR) Receives a Hold from J.P. Morgan

- TipRanks. All rights reserved.

News

Stocktwits